AbbVie (ABBV): Buy, Sell, or Hold Post Q3 Earnings? [Yahoo! Finance]
Abbott Laboratories (ABT)
Last abbott laboratories earnings: 4/16 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
abbott.com/investors.html
Company Research
Source: Yahoo! Finance
This performance may have investors wondering how to approach the situation. Is now still a good time to buy ABBV? Or are investors being too optimistic? Find out in our full research report, it's free for active Edge members Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE:ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions. Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right. With $59.64 billion in revenue over the past 12 months, AbbVie is one of the most scaled enterprises in healthcare. This is
Show less
Read more
Impact Snapshot
Event Time:
ABT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABT alerts
High impacting Abbott Laboratories news events
Weekly update
A roundup of the hottest topics
ABT
News
- Rep. Julia Letlow Discloses Over 200 Stock Trades After Deadline As Ban Debate Grows In Congress [Forbes]Forbes
- Abbott Laboratories (NYSE:ABT) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $157.00 to $152.00. They now have a "buy" rating on the stock.MarketBeat
- AI Optical Coherence Tomography Market Opportunities to 2029 & 2034 by Type, Technology, Application and Region [Yahoo! Finance]Yahoo! Finance
- Why Abbott Laboratories (ABT) Story Is Shifting With Exact Sciences Deal Talk And Legal Wins [Yahoo! Finance]Yahoo! Finance
- PainTEQ Announces Appointment of Lalit Venkatesan, PhD as Senior Vice President of Clinical Research [Yahoo! Finance]Yahoo! Finance
ABT
Earnings
- 10/15/25 - In-Line
ABT
Sec Filings
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- ABT's page on the SEC website